A uncommon, inherited endocrine dysfunction whose normal therapies are steroids that introduce a variety of unwanted effects now has a new FDA-approved remedy,...
Neuroscience drug developer Lundbeck is increasing its scope to epilepsy by way of the $2.6 billion acquisition of Longboard Prescribed drugs, an organization...